Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Phase IIa studies indicate GFT-505 may reduce remnant cholesterol

May 21, 2013

Merck & Co. discloses new GPR131 receptor agonists

May 17, 2013

AstraZeneca designs matched triplicate approach for optimization of drug pharmacokinetics

May 17, 2013

PI3Kdelta inhibition delays the progression of autoimmune diabetes

May 17, 2013

Researchers at Torrent Pharmaceuticals synthesize new TGR5 agonists

May 16, 2013

Chinese group presents new DGAT1 inhibitors

May 16, 2013

Sanofi discloses novel PKC-beta inhibitors

May 16, 2013

Piramal Enterprises receives IND approval for P-11187

May 15, 2013

Sirtris Pharmaceuticals discloses new hSIRT1 activators

May 14, 2013

Lexicon advances LX-4211 to expansion portion of phase II trial

May 14, 2013

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...